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www.cdatm.orgAbstractObjectives: Drugs for targeted therapy have become a new strategy of adjuvant therapy for treatment of lung cancer. The Keap1
(kelch-like ECH-associated protein 1)eNrf2 (nuclear factor erythroid 2-related factor 2) pathway is recognized to be critical in
regulating genes related to the cellular protective response and protecting cells from oxidative damages and toxic insult.
Methods: Pubmed, Embase, OVID, and the Cochrane Library databases were searched from the beginning of each database
without any limitations to the date of publication. Search terms were “Nrf2” or “Keap1” and “Lung cancer”.
Results: The upregulation of Nrf2 had been closely related to tumor protection and drug resistance. The aberrant state of Keap1 or
Nrf2 that were frequently found in lung cancer conferred a poor prognosis. Nrf2 could prevent cells from undergoing oncogenesis
as a tumor suppressor, while it could also promote cancer progression and resistance to chemotherapeutic drugs as an oncogene,
depending on the different stages of tumor progression. Target Nrf2 signaling by specific chemicals showed it could prevent tumor
growth or combat chemoresistance.
Conclusions: Increasing evidence has demonstrated the dual roles of the Keap1eNrf2 pathway in tumor initiation and progres-
sion. In this paper, we provide a comprehensive overview of the potency of the Keap1eNrf2 pathway as an antitumor target, and the
current status of Nrf2 activators or inhibitors for therapeutic approaches. Further studies are required to clarify the role of Nrf2 in
lung cancer at different tumor stages, in order to maximize the efficacy of Keap1eNrf2 targeting agents.
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Cancer cells are frequently exposed to multiple
stresses and toxicants both from intracellular and
extracellular events. To protect against these insults,
eukaryotic cells have developed complex defense
systems for adjusting cells to oxidative and xenobiotic
stresses. Nuclear factor erythroid 2-related factor 2
(Nrf2), also known as Nuclear factor (erythroid-
derived 2)-like 2 (NFE2L2) and its natural inhibitor
Kelch-like erythroid cell derived protein with CNC
homology (ECH)-associated protein 1 (Keap1) are
essential in the regulation of cytoprotective and
detoxifying defense systems, including phase I (cyto-
chrome P450s) and phase II (detoxifying, and antiox-
idant proteins) enzymes.1,2 Activation of Nrf2 protects
against inflammatory injury in the HTR-8/SVneo
human first trimester extravillous trophoblast cell line
and steatosis in nutritionally induced non-alcoholic
steatohepatitis in mice.3,4 Although the Nrf2-null
mice are viable and show no obvious phenotype
defect, they seem to be more sensitive than wild-type
mice to oxidative damage and a toxic environment,
such as exposure to ultraviolet radiation B, furosemide,
acetaminophen, and cigarette smoke.5e9 The alter-
ations of genes in the Keap1eNrf2 pathway were
commonly found to exist in lung cancer and to be
closely related with tumor progression. Therefore,
fully understanding the role of Nrf2 in the regulation of
cytoprotective events may provide insights into the
search of novel anticancer targets, and further benefit
the chemotherapy outcome in lung cancer. In review-
ing the dual-role of Nrf2 in lung cancer, we focus here
on discussing the potency of the Keap1eNrf2 pathway
as an antitumor target for either prevention or therapy.Fig. 1. Schematic representation of Nrf2 and Keap1 protein domains. (A)
mains. (B) The Keap1 protein mainly comprises five functional domains.The Keap1eNrf2 pathway
Nrf2
Molecular dissection of Nrf2 identified seven Neh
(Nrf2-ECH homologous structure) domains, known as
Neh1-Neh7 (Fig. 1A). The Neh2 domain, located in the
N-terminal region ofNrf2, is essential for regulatingNrf2
stability. It contains two binding sites (the DLG and
ETGEmotifs) responsible forKeap1 binding10 and seven
lysine residues important for ubiquitin conjugation.10,11
The Neh1 domain has been shown to heterodimerize
with Maf and bind to the ARE within DNA since it
contains a CNC-type bZIP DNA-binding motif.12 The
Neh3, Neh4 and Neh5 domains are required for the
transcriptional activation of Nrf2 target genes.13,14 The
Neh7 domain was found to interact with RXRa (retinoic
X receptor a), which functions as an Nrf2 repressor and
repress the target gene transcription.15
Keap1
Keap1 mainly contains five functional domains
(Fig. 1B) including the NTR (the N-terminal region),
BTB (the broad complex, tramtrack, and bric-a-brac),
IVR (intervening linker domain), DGR (double
glycine/Keclch repeats) and CTR (the C-terminal re-
gion).16 The DC domain (including DGR and CTR) is
responsible for binding to Neh2 of Nrf2, while the
BTB domain is required for the dimerization of two
Keap1 molecules.10,17 The BTB with a part of IVR
bind Cullin3 (Cul3) to form ubiquitin E3 ligase, in
which Keap1 serves as a substrate adaptor for Nrf2
degradation.18 The IVR and BTB contain several
cysteine residues, modifications of which underNrf2 mainly contains seven conserved domains named the Neh do-
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Keap1 activity and Nrf2 stability.19
Target genes of Nrf2
Nrf2 belongs to the cap'n’collar (CNC)-bZip (basic
leucine zipper) family of transcription factor. Under
basal conditions, Nrf2 is anchored in the cytoplasm and
inhibited by Keap1 and maintained at a low expression
level. Once activated, Nrf2 translocates into the nu-
cleus, heterodimerizes with small Maf proteins and
regulates antioxidant response element- (ARE-) medi-
ated transcriptions of various genes encoding antioxi-
dant enzymes and metabolic proteins classified as phase
II enzymes.20 A series of genes encoding cellular
detoxification enzymes and antioxidant proteins are
regulated by Nrf2, including several categories as fol-
lows: (1) proteins related to synthesis and conjugation
of glutathione: glutamate cysteine ligase (GCL:GCLC
and GCLM), glutathione reductase (GSR), etc;21 (2)
antioxidant proteins that maintain redox-balancing:
thioredoxin (Trx), peroxidase (Prx), etc;22,23 (3) drug
metabolizing enzymes: NAD (P) H quinone oxidore-
ductase 1 (NQO1), etc;21 (4) proteins involved in drug
delivery: multiple drug resistant associated proteins
(MRPs), etc;24 (5) Heme and iron metabolism: Heme
oxygenase 1 (HO-1), etc.21 Thus, the Nrf2-mediated
antioxidant response defends cells from multiple
stresses including oxidative stresses and toxic damages.
Regulation of Keap1eNrf2 pathway
Keap1-dependent regulation of Nrf2
Under basal conditions, Keap1 functions as a sub-
strate adaptor protein for the Cul3-containing E3
ubiquitin ligase complex, which targets Nrf2 for ubiq-
uitination and degradation.25 The “hinge and latch”
model proposed that two Keap1 molecules in the
dimmer interact with one Nrf2 molecule at two binding
sites, the high-affinity ETGE (hinge) motif and the low-
affinity DLG (latch) motif, which position Nrf2 to un-
dergo poly-ubiquitinations and degradation by the 26S
proteasome.26 Thus, Nrf2 is sequestered in the cyto-
plasm by Keap1 and maintained at a low level (Fig. 2).
Under stressed conditions, it has been proposed that
covalent modifications of the critical cysteine residues
within Keap1 lead to Nrf2 release, since Keap1 is a thiol-
rich protein and is thus sensitive to an electrophile.27 It
was found that de novo synthesized Nrf2 accumulated in
the cytoplasm and translocates into the nucleus rather
than Nrf2 dissociated from Keap1.28 Besides, theCul3eKeap1 interaction was disrupted due to oxidative
stress as in the case of modification at Cys151 in BTB
domain,29 which also resulted in a decrease of Nrf2
degradation. As a result, the inhibition of Nrf2 was
hindered. Nrf2 was then allowed to accumulate in the
cytoplasm and translocate into the nucleus for tran-
scription of target genes (Fig. 2). There are three residues
(Cys151, Cys273, and Cys288) that are critical for the
normal function of Keap1. Cys273 and Cys288, located
in the IVR domain, were found to be required for Keap1-
dependent ubiquitination of Nrf2 under basal condi-
tions.30 Cys151 in the BTB domain is important in the
de-repression ofNrf2 both under basal culture conditions
and upon exposure of cells to Nrf2 inducers. Modifica-
tion of Cys151 probably impedes the Keap1eCul3
interaction and prevents the ubiquitination of Nrf2,
resulting in the termination of Nrf2 degradation.31
Keap1-independent regulation of Nrf2
Besides the Keap1-dependent regulation of Nrf2,
there are several alternative mechanisms related to
Nrf2 activation such as phosphorylation, acetylation,
and cysteine modification of Nrf2. Pathways involved
include protein kinase C (PKC), glycogen synthase
kinase-3 beta (GSK3b), mitogen-activated protein ki-
nase (MAPK) cascades, the phosphatidylinositol 3-
kinase pathway (PI3K/AKT), and extracellular regu-
lated protein kinases (ERK), etc. PKC phosphorylates
Ser-40 of Nrf2 in its Neh2 domain, resulting in the
disassociation between Nrf2 and Keap1.32 GSK-3b
phosphorylates the tyrosine kinase Fyn and induces its
nuclear accumulation.33 Fyn has been shown to phos-
phorylate Nrf2 at tyrosine-568, facilitating its nuclear
export and degradation. In cells with mutant Nrf2
(Y568A), nuclear accumulation of Nrf2 occurs attrib-
uting to the loss of the ability to be phosphorylated at
tyrosine-568.34 Thus, the phosphorylation modification
and subsequent nuclear accumulation of Fyn mediated
by GSK-3b confer the nuclear export of Nrf2.35e37 In
addition, GSK3b is a downstream target of multiple
kinase cascades, such as Akt and MAPK, which are
involved in Nrf2 regulation. Thus, GSK3b is essential
in controlling the nuclear export, ubiquitination, and
subsequent proteasomal degradation of Nrf2, and is
also important in the down-regulation of Nrf2-
dependent transcription in cell antioxidant defense.38
The histone acetyltransferase hMOF is another pro-
tein that can regulate Nrf2 independent of Keap1.
hMOF is reported to be acetylated Nrf2 at Lys 588,
which increased nuclear accumulation of Nrf2 and
enhanced the transcription of its downstream genes.39
Fig. 2. The hinge-latch model of Nrf2. Nrf2 is negatively regulated by Keap1 under unstressed conditions. Two Keap1 molecules interact with one
Nrf2 molecule at two binding sites, the ETGE and DLG motifs. Keap1 functions as a substrate adaptor protein for the Cullin3 (Cul3)-containing
E3-ligase complex and targets Nrf2 for ubiquitination and degradation. Under stress conditions, the inhibition of Nrf2 is undermined. The de novo
synthesized Nrf2 accumulates in the cytoplasm and translocates into the nucleus, functioning as a transcriptional factor.
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Dysfunction of Keap1 in lung cancer
A growing number of studies indicate that abnormal
states of the Keap1eNrf2 pathway exist in lung cancer,
including somatic mutations, loss of heterozygosity or
DNA methylations in the promoter region of Keap1, and
Nrf2 mutations.40e45 Somatic alterations in Keap1 were
first found both in lung cancer cell lines and in lung
cancer tumor tissues.41 The aberrant Keap1 disrupts the
association between Keap1 and Nrf2, resulting in
increased Nrf2 accumulation and downstream gene
transcription. The Cancer Genome Atlas (TCGA)
recently profile 178 lung squamous cell carcinomas
(SQCC) for comprehensive genomic characterization.
The data revealed that mutations or deletions in Nrf2,
Keap1, and CUL3 occurred in 34% of tumors.40 Mutant
Keap1 or Cul3 have been reported to lose their normal
function.40 Another study reviewed 213 somatic muta-
tions in Keap1, and then characterized 18 common mu-
tations in lung SQCC. Of these 18 mutations, four
(L231V, S224Y, P318L, and R71L) did not affect the
inhibitory effect on NRF2, five (N469fs, P318fs, G333C,R554Q, and W544C) impacted the Keap1eNrf2 asso-
ciation and the Keap1 activity of suppressing Nrf2, the
remaining mutation sites showed hypomorphic suppres-
sion of Nrf2. Surprisingly, several mutations enhanced
the binding of Keap1 and Nrf2, but this enhancement
impaired degradation of Nrf2 while retaining the ability
to ubiquitinate Nrf2.46 Anju Singh et al. performed a
systematic analysis of the Keap1 genomic locus on a
Caucasian population of 54 cases of non-small cell lung
cancer (NSCLC) samples and 12 lung cancer cell lines, in
which deletions, insertions, missense mutations of
Keap1, and loss of heterozygosity at 19p13.2 were
commonly found.41 All somatic mutations are located in
the highly conserved Kelch binding or IVR domain,
which are important functional regions for Keap1eNrf2
binding or for Keap1 associating with Cul3, respectively.
Another study that assessed 65 lung cancer samples of
Japanese patients confirmed a similar result: non-
synonymous mutations or reduced expression levels of
Keap1 were identified both in patients' samples and in
different lung cancer cell lines. Low Keap1 activity has
been reported to lead to Nrf2 activation and subsequent
up-regulation of target genes, which will favor tumor
growth and drug resistance.42 Besides, high methylation
of the Keap1 promoter are found in both lung cancer cell
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is found when compared with a normal bronchial
epithelial cell line.43 In addition, Keap1 alterations are
very common events in lung papillary adenocarcinoma
(60%) and the rates of Keap1 mutations may vary in
different histological lung tumor types.47
Nrf2 mutations in lung cancer
Keap1 mutations or inactivation are not the only
reason for elevated Nrf2, the somatic mutations of Nrf2
itself occurs in lung cancer cells.40,44,45 Intriguingly, it
has been found that almost all mutations in Nrf2 were
specifically within either the DLG or ETGE motifs,
domains of Nrf2 that interact with Keap1, and were
mutually exclusivewithmutations in Keap1.40 A similar
result was seen in another two studies, including one
study that collected 1145 cancer tissues from various
histological carcinomas.44,45 Somatic mutations were
identified in the coding region of Nrf2 and all mutations
found were missense substitutions.45 Cells with mutant
Nrf2 are insensitive to Keap1-mediated regulation and
display aberrant cellular accumulation of Nrf2 as well as
constitutive induction of cytoprotective enzymes and
drug efflux pumps.45 Interestingly, gain-of-function
mutations in Nrf2 are found more frequently in multi-
ple types of squamous cell carcinomamalignant tumors,
including lung cancer.44,48
Nrf2 plays a complicated role in lung cancer
The dual roles of Nrf2 in lung cancer: the role of
tumor suppressor
At first glance, Nrf2 was thought to be a protective
gene and could prevent humans from many oxidative
stress related diseases such as inflammation,6 neuro-
degenerative disorders,49 and pulmonary fibrosis.50
Nrf2 deficient (Nrf2/) mice exhibit increased
susceptibility to tumorigenesis.51 Notably, many
chemopreventive drugs have been identified as Nrf2
inducers, such as sulforaphane,52 curcumin,53 EGCG
(epigallocatechin-3-gallate),54 resveratrol,55 olti-
praz,56 the synthetic triterpenoid CDDO (2-cyano-
3,12-dioxooleana-1,9 (11)-dien-28-oic acid) and its
imidazolide (CDDO-Im), and methyl ester (CDDO-
Me) derivatives.57 All these compounds have been
shown to defend cells from carcinogens by inducing
the Nrf2-dependent transcriptions, including multiple
phase II detoxifying enzymes and antioxidants. The
protective role of Nrf2 was also verified in the pro-
motion or progression phase of lung cancer.Suppression of Nrf2 by Keap1-directed ubiquitylation
or by Nrf2 shRNA/siRNA enhanced cell migration
and plasticity in A549 cells.58 Additionally, Nrf2-
deficient mice display increased susceptibility to
pulmonary metastasis of the mouse Lewis lung car-
cinoma tumors.59
The dual roles of Nrf2 in lung cancer: the role of
tumor promoter
Although Nrf2 showed its protective role in
tumorigenesis, accumulating evidence has started to
point out the “dark” side of Nrf2 in cancers. The
elevation of Nrf2 protein levels were found in multi-
ple types of human cancers and were associated with
tumor promotion and progression,60e62 which was
reasonable since elevated Nrf2 was favored by ma-
lignant cells to protect them from the environmental
stress. As a matter of fact, the mutations of either
Keap1 or Nrf2 commonly existed in lung can-
cer,41e45,47,63 contributing to tumor growth advan-
tages,42,64,65 chemoresistance,41,42,65e68 radio
resistance,69,70 and a poor outcome.71 The increased
levels and activities of Nrf2 have been shown to
promote cancer cell proliferation, since the cell
growth was stimulated in lung cancer-derived cell
lines with Nrf2 activation due to mutations or low
expression of Keap1.42 Additionally, silencing of Nrf2
using shRNA or siRNA caused an inhibition of the
proliferation of A549 cells,64,65 a human lung cancer
cell line with mutated Keap1 and elevated levels of
Nrf2.41 Cells with dysfunctional Keap1 showed less
sensitivity to etoposide and carboplatin than those
with wild-type Keap1, suggesting the abnormal state
of Keap1eNrf2 confers chemoresisrance.41 A later
similar study in 65 Japanese patients with lung cancer
also verified that loss of Keap1 function (due to mu-
tations or low-level expression) increased nuclear
accumulation and induced constitutive activation of
Nrf2, leading to the expression of its target genes, and
thus resulted in growth advantages and cisplatin
resistance of lung cancer cells.42 Silencing of Nrf2
through RNAi sufficiently reversed resistance to
cisplatin in NSCLC cells65,67,68 and improved sensi-
tivity of A549 to doxorubicin and etoposide.67 The
elevated level of Nrf2 also led to radioresistance
through regulation of reactive oxygen species (ROS)
in human lung cancer.69,70 Thus, all these growth
advantages conferred by Nrf2 over-activation result in
poor outcomes of lung cancer and make Nrf2 an in-
dependent prognostic factor for survival analysis of
patients with lung cancer.71
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Nrf2 activators: defenders of cancer prevention
Nrf2 activators are chemoprevention agents due to
their role of oxidation protection. Plenty of compounds
with anticarcinogenic activities have been identified as
potent Nrf2 inducers, most of which are from natural
plants and foods (Fig. 3). One of them is sulforaphane
(SFN), an isothiocyanate isolated from broccoli
(cruciferous vegetables).72 Sulforaphane has been
proven to inhibit the growth of lung carcinomas in A/J
mice treated with carcinogens.73 Sulforaphane modu-
lates the genes involved in tumor proliferation,
apoptosis, angiogenesis and the metastatic process, thus
it has proved effective in different stages of carcino-
genesis.74 The chemoprevention of sulforaphane may
be due to its induction of the expressions of Nrf2 and its
target genes. At first, sulforaphane was identified as the
most potent inducer of NQO1.52 Later, the induction of
NQO1 by sulphoraphane was recognized to actually be
regulated through the Keap1eNrf2eARE signaling
pathway.75 Sulforaphane elevates expression of Nrf2
protein rapidly in less than 30 min with the transcrip-
tional activation of its target genes up-regulated
concomitantly; genes such as HO-1, NQOs, GSTs,
and UGTs.76 Keap1 is a sulfhydryl-rich protein, thus
electrophiles, like sulforaphane, can react with Cys
residues in the Keap1 protein to form thionoacyl ad-
ducts.77 The thionoacyl adducts at several particular Cys
residues may disrupt the association between Cul3 and
Keap1, resulting in the failure of Nrf2 ubiquitination.78
As a consequence, newly synthesized Nrf2 escape
degradation and translocates to the nucleus as the active
form and facilitates the transcription of its target genes.
In addition, sulforaphane might regulate intracellular
localization and protein stability of Nrf2 through a
series of intracellular kinases.79 Several clinical trials
have been completed or are underway to evaluate
the bioavailability, safety, tolerance, and metabolism
in healthy people, or the effect and safety in humans
with different cancers (https://www.clinicaltrials.gov/ct2/
results?term¼sulforaphane&Search¼Search). Although
all these clinical trials are still in relatively early phases,
they will prepare the way for sulforaphane to become a
new safe drug and the Keap1eNrf2eARE pathway
can thereby become an attractive target for treating
chemoprevention during carcinogenesis.
The famous polyphenol compound curcumin, that
has antitumor activity, is derived from the Indian spice
turmeric plant80 and has also been found to be an Nrf2inducer.53 Numerous and constant studies recognized
curcumin as a chemotherapeutic drug, whose inhibi-
tory activities on tumor growth work throughout the
stages of tumor progression; including initiation, pro-
motion, proliferation, angiogenesis, and metastasis.80
Daily oral curcumin (80 mg/kg for 2 weeks) adminis-
tered to Wistar rats exposed to cigarette smoke (CS)
attenuated the CS-induced changes of pulmonary his-
tology and decreased inflammation.81 Curcumin also
exerts its protective effect against nicotine-induced
lung toxicity by modulating the biochemical marker
enzymes; including nicotine-induced alkaline phos-
phatase, lactate dehydrogenase, and lipid peroxidation
levels, decreasing the lipid peroxidation and aug-
menting the antioxidant defense system.82 More recent
reports showed that supplementation of curcumin
effectively modulates premature mitochondria senes-
cence and related ultrastructural changes during benzo
[a]pyrene (BP)-induced lung carcinogenesis in mice.83
Moreover, curcumin reversed cisplatin (DDP) resis-
tance in A549/DDP cells (DDP-resistant lung adeno-
carcinoma cells).84 Although the anticancer effects of
curcumin have been revealed to be achieved through
regulating multiple biochemical pathways and various
molecules involved in carcinogenesis, several re-
searches verified that Nrf2 plays a vital role in carci-
nogenesis prevention as well as the antitumor activity
of curcumin. In epithelial cells, curcumin has been
showed to stimulate the expression of Nrf-2 in a con-
centration- and time-dependent manner resulting in a
significant increase in HO-1 protein expression and
activity.85 Curcumin has been proven to be pharma-
cologically safe in the early-phase clinical trials. The
effects of curcumin on cancer patients with NSCLC or
other cancers have also been investigated in relevant
clinical trials (https://www.clinicaltrials.gov/ct2/results
?term¼curcumin&Search¼Search).86
In addition, several other natural compounds such as
()-epigallocatechin-3-gallate (EGCG), caffeic acid
phenethyl ester (CAPE), and resveratrol show the ability
to inhibit cancer growth via theNrf2-dependent pathway.
EGCG is the most abundant one of the major poly-
phenolic catechins presented in green tea, with potent
antioxidant and chemopreventive activities.87 The anti-
tumor effect of EGCG has been validated in different
types of cancers including lung cancer.88 The antitumor
effect of EGCG is partly through inducing the NRF2
signaling pathway.54 Caffeic acid phenethyl ester
(CAPE), an active component extracted from propolis,
has the activities of cancer prevention and antitumor
action in various types of cancer.89 Nrf2 is also proven to
be one of the molecular targets of CAPE in cancer
Fig. 3. The structure and origins of natural molecules that have activity to incite or inhibit Nrf2.
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in grapes and peanuts, has been shown to prevent or
delay the development of malignancies in a broad va-
riety of in vivo preclinical models of carcinogenesis.90
Likewise, this stilbenoid, polyphenol phytochemical is
one of the widely known natural Keap1eNrf2 activa-
tors.55 These Nrf2 inducers described above have allbeen in several clinical evaluations for safety and
bioavailability, which promote the Keap1eNrf2 acti-
vators from preclinical experiments to clinical appli-
cation (https://www.clinicaltrials.gov/ct2/results?term
¼EGCG&Search¼Search; https://www.clinicaltrials.
gov/ct2/show/NCT02114892?term¼Resveratrol&
rank¼3).
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Since Nrf2 also plays a role in oncogenesis under
given situations, it is thereby considered that inhibition
of Nrf2 could turn into a promising strategy for cancer
treatment. In contrast to the numerous chemicals and
molecules reported to be Nrf2 inducers, the ones
identified as Nrf2 inhibitors are very few. Several
natural compounds known as Nrf2 inhibitors are listed
in Fig. 3. Brusatol, a quassinoid isolated from the
Brucea javanica shrub, was identified as a unique in-
hibitor of the Nrf2 pathway. Treatment with brusatol
sensitized a broad spectrum of cancer cells to the
antitumor drugs, reduced tumor burden, and improved
survival in murine A549 xenograft models.68,91 The
inhibitory effect of brusatol toward Nrf2 was shown to
be rapid, transient,92 and acted through enhanced
ubiquitination and degradation of Nrf2.91
Luteolin (30,40,5,7-tetrahydroxyflavone), a flavonoid
present in many types of plants like celery, perilla leaf,
peppers, broccoli, and parsley, was demonstrated to be
a strong inhibitor of Nrf2 in vitro.93 Treatment with
luteolin significantly enhanced the antitumor efficacy
of chemotherapeutics including oxaliplatin, doxoru-
bicin, and bleomycin on A549 cells.93 The study per-
formed on murine A549 xenograft models showed that
luteolin greatly inhibited the growth of A549 cells and
enhanced anti-cancer efficacy of cisplatin in vivo.94
Inhibition of the Nrf2 pathway using luteolin
reversed the resistance of colorectal cancer cell lines
toward chemotherapeutic drugs.95 In addition, luteolin
is able to inhibit the proliferation, cell cycle progres-
sion, and induce apoptosis of cancer cells derived from
nearly all types of tumors; including gastric cancer,
prostate cancer, melanoma, epidermoid carcinoma,
leukemia, pancreatic tumor, hepatoma, and so on.96
Although no clinical trial of luteolin treatment for
cancer has been carried out to our knowledge, there is a
Phase II study completed on the effects of luteolin on
behavior in children with autism spectrum disorders
(https://www.clinicaltrials.gov/ct2/show/NCT018475
21?term¼Luteolin&rank¼1).
The alkaloid trigonelline is another molecule iden-
tified recently as an Nrf2 inhibitor with antitumor ac-
tivity. Treatment of trigonelline combined with
etoposide enhanced the antitumor efficacy of etoposide
and reduced tumor sizes in Colo357 and Panc1 tumor
bearing-SCID-beige mice.97 In a rat ascites hepatoma
cell line, trigonelline showed inhibitory effects on the
invasion of AH109A hepatoma cells.98 Studies have
revealed Nrf2 as an important contributor to tumorgrowth and chemoresistance, thus these Nrf2 inhibitors
have emerged as useful therapeutic tools for the
effective improvement of anticancer therapy.
Perspectives
Lung cancer has been the first leading cause of
cancer-related death around the world.99 The overall
prognosis for NSCLC patients has been greatly
improved owing to the development of targeting ther-
apy.100 Although tyrosine kinase inhibitors (TKIs)
have attracted tremendous attention in the last ten
years, acquired resistance has put the further devel-
opment of TKIs into a dilemma. Multi-target therapy
shows its advantage in the immediate response that
abolishes tumor before the occurrence of resistance.
Undoubtedly, the Keap1eNrf2 signaling pathway is a
potential target mediating tumor progression and sur-
vival. Targeting Nrf2 has been found to be a promising
strategy for the treatment of lung cancer associated
with altered functions of Nrf2, yet further studies are
needed to fully exploit the role of Nrf2 in tumor pro-
gression and prevention. On one side, Nrf2 activators
may prevent tumor initiation and progression. The
activation of the Nrf2 pathway directly impedes tumor
growth and causes tumor regression. On the other side,
Nrf2 activators may also lead to the acquisition of
tumor resistance to cancer therapies, because the
elevated level of Nrf2 prevents tumor cells from being
destroyed due to the harsh microenvironment or
chemotherapy treatment. In this context, once we
decide to target Nrf2 for treatment, problems will come
about as to which one to choose and when to use the
Nrf2 activators or inhibitors. From our current
perspective, Nrf2 activators are preferred in an early
stage tumor, and Nrf2 inhibitors will be beneficial in
treating late stage neoplasms. Nevertheless, a widely
approved criterion or guideline is desperately needed
to standardize chemotherapies targeting Nrf2.
Both Nrf2 activators and inhibitors used in the
ongoing experiments lack high specificity, resulting in
a weak relationship between Nrf2 regulation and tumor
growths. For example, plant-derived activator of Nrf2
such as curcumin actually regulate through alternative
pathways other than Nrf2. Small molecule activators or
inhibitors with ideal specificity of Nrf2 would directly
target this signaling pathway, and the promising effects
would be easier to illustrate. The Nrf2 inhibitors
identified to date are far fewer than Nrf2 activators,
thus more chemicals and molecules that inhibit Nrf2
need to be designed and explored. With regard to the
clinical application, intensive studies on Nrf2
183Y.-H. Tong et al. / Chronic Diseases and Translational Medicine 1 (2015) 175e186inhibitors are needed to define the bioavailability,
safety and clinical effects.
Conflicts of interest
All authors declare no potential conflicts of interest,
including specific financial interests and relationships
and affiliations relevant to the subject of this manuscript.
Acknowledgement
This work was supported by Zhejiang Provincial
Program for the Cultivation of High-level Innovative
Health Talents (No: 2010-190-4, Lin Nengming), Sci-
ence and Technology Project of Zhejiang Province (No:
2012C23073, Lin Nengming), Natural Science Foun-
dation of Zhejiang Province, China (No: LY13H310003,
Fan Yun), and Medical Science Research Foundation of
Zhejiang Province (No: 2014KYA008, Tong Yinghui).
References
1. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev
Pharmacol Toxicol. 2013;53:401e426.
2. Miao W, Hu L, Scrivens PJ, Batist G. Transcriptional regulation of
NF-E2 p45-related factor (NRF2) expression by the aryl hydro-
carbon receptor-xenobiotic response element signaling pathway:
direct cross-talk between phase I and II drug-metabolizing en-
zymes. J Biol Chem. 2005;280:20340e20348.
3. Park HR, Loch-Caruso R. Protective effect of nuclear factor E2-
related factor 2 on inflammatory cytokine response to bromi-
nated diphenyl ether-47 in the HTR-8/SVneo human first
trimester extravillous trophoblast cell line. Toxicol Appl Phar-
macol. 2014;281:67e77.
4. Lee LY, Kohler UA, Zhang L, et al. Activation of the Nrf2-ARE
pathway in hepatocytes protects against steatosis in nutritionally
induced non-alcoholic steatohepatitis in mice. Toxicol Sci.
2014;142:361e374.
5. Chan K, Lu R, Chang JC, Kan YW. NRF2, a member of the NFE2
family of transcription factors, is not essential for murine eryth-
ropoiesis, growth, and development. Proc Natl Acad Sci U S A.
1996;93:13943e13948.
6. Saw CL, Yang AY, Huang MT, et al. Nrf2 null enhances UVB-
induced skin inflammation and extracellular matrix damages.
Cell Biosci. 2014;4:39.
7. Qu Q, Liu J, Zhou HH, Klaassen CD. Nrf2 protects against
furosemide-induced hepatotoxicity. Toxicology.
2014;324:35e42.
8. Reisman SA, Csanaky IL, Aleksunes LM, Klaassen CD. Altered
disposition of acetaminophen in Nrf2-null and Keap1-knockdown
mice. Toxicol Sci. 2009;109:31e40.
9. Gebel S, Diehl S, Pype J, et al. The transcriptome of Nrf2-/- mice
provides evidence for impaired cell cycle progression in the
development of cigarette smoke-induced emphysematous
changes. Toxicol Sci. 2010;115:238e252.
10. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M.
Keap1 recruits Neh2 through binding to ETGE and DLG motifs:characterization of the two-site molecular recognition model.
Mol Cell Biol. 2006;26:2887e2900.
11. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1
is a redox-regulated substrate adaptor protein for a Cul3-
dependent ubiquitin ligase complex. Mol Cell Biol.
2004;24:10941e10953.
12. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear
activation of antioxidant responsive elements by Nrf2 through
binding to the amino-terminal Neh2 domain. Genes Dev.
1999;13:76e86.
13. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A,
Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a
CREB binding protein, and synergistically activate transcription.
Genes Cells. 2001;6:857e868.
14. Nioi P, Nguyen T, Sherratt PJ, Pickett CB. The carboxy-terminal
Neh3 domain of Nrf2 is required for transcriptional activation.
Mol Cell Biol. 2005;25:10895e10906.
15. Wang H, Liu K, Geng M, et al. RXRalpha inhibits the NRF2-
ARE signaling pathway through a direct interaction with the
Neh7 domain of NRF2. Cancer Res. 2013;73:3097e3108.
16. Adams J, Kelso R, Cooley L. The kelch repeat superfamily of
proteins: propellers of cell function. Trends Cell Biol.
2000;10:17e24.
17. Yamamoto T, Suzuki T, Kobayashi A, et al. Physiological sig-
nificance of reactive cysteine residues of Keap1 in determining
Nrf2 activity. Mol Cell Biol. 2008;28:2758e2770.
18. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-
BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3
ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell
Biol. 2004;24:8477e8486.
19. Ogura T, Tong KI, Mio K, et al. Keap1 is a forked-stem dimer
structure with two large spheres enclosing the intervening,
double glycine repeat, and C-terminal domains. Proc Natl Acad
Sci U S A. 2010;107:2842e2847.
20. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heter-
odimer mediates the induction of phase II detoxifying enzyme
genes through antioxidant response elements. Biochem Biophys
Res Commun. 1997;236:313e322.
21. Chorley BN, Campbell MR, Wang X, et al. Identification of
novel NRF2-regulated genes by ChIP-Seq: influence on retinoid
X receptor alpha. Nucleic Acids Res. 2012;40:7416e7429.
22. Kim YC, Masutani H, Yamaguchi Y, Itoh K, Yamamoto M,
Yodoi J. Hemin-induced activation of the thioredoxin gene by
Nrf2. A differential regulation of the antioxidant responsive
element by a switch of its binding factors. J Biol Chem.
2001;276:18399e18406.
23. Ishii T, Yanagawa T. Stress-induced peroxiredoxins. Subcell
Biochem. 2007;44:375e384.
24. Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. In-
duction of the multidrug resistance-associated protein family of
transporters by chemical activators of receptor-mediated path-
ways in mouse liver. Drug Metab Dispos. 2005;33:956e962.
25. Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor
Keap1 functions as an adaptor for Cul3-based E3 ligase to
regulate proteasomal degradation of Nrf2. Mol Cell Biol.
2004;24:7130e7139.
26. Tong KI, Kobayashi A, Katsuoka F, Yamamoto M. Two-site
substrate recognition model for the Keap1-Nrf2 system: a hinge
and latch mechanism. Biol Chem. 2006;387:1311e1320.
27. McMahon M, Lamont DJ, Beattie KA, Hayes JD. Keap1 per-
ceives stress via three sensors for the endogenous signaling
184 Y.-H. Tong et al. / Chronic Diseases and Translational Medicine 1 (2015) 175e186molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U
S A. 2010;107:18838e18843.
28. Kobayashi A, Kang MI, Watai Y, et al. Oxidative and electro-
philic stresses activate Nrf2 through inhibition of ubiquitination
activity of Keap1. Mol Cell Biol. 2006;26:221e229.
29. Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC,
Freeman ML. Covalent modification at Cys151 dissociates the
electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem
Res Toxicol. 2008;21:705e710.
30. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are
required for Keap1-dependent ubiquitination of Nrf2 and for
stabilization of Nrf2 by chemopreventive agents and oxidative
stress. Mol Cell Biol. 2003;23:8137e8151.
31. Eggler AL, Small E, Hannink M, Mesecar AD. Cul3-mediated
Nrf2 ubiquitination and antioxidant response element (ARE)
activation are dependent on the partial molar volume at position
151 of Keap1. Biochem J. 2009;422:171e180.
32. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-
40 by protein kinase C regulates antioxidant response element-
mediated transcription. J Biol Chem. 2002;277:42769e42774.
33. Jain AK, Jaiswal AK. GSK-3beta acts upstream of Fyn kinase in
regulation of nuclear export and degradation of NF-E2 related
factor 2. J Biol Chem. 2007;282:16502e16510.
34. Jain AK, Jaiswal AK. Phosphorylation of tyrosine 568 controls
nuclear export of Nrf2. J Biol Chem. 2006;281:12132e12142.
35. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD,
Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase ki-
nase 3-dependent degradation of the Nrf2 transcription factor in a
Keap1-independent manner. Mol Cell Biol. 2011;31:1121e1133.
36. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD.
Redox-regulated turnover of Nrf2 is determined by at least two
separate protein domains, the redox-sensitive Neh2 degron and
the redox-insensitive Neh6 degron. J Biol Chem.
2004;279:31556e31567.
37. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A,
Hayes JD. Nrf2 is controlled by two distinct beta-TrCP recog-
nition motifs in its Neh6 domain, one of which can be modulated
by GSK-3 activity. Oncogene. 2013;32:3765e3781.
38. Rojo AI, Sagarra MR, Cuadrado A. GSK-3beta down-regulates
the transcription factor Nrf2 after oxidant damage: relevance to
exposure of neuronal cells to oxidative stress. J Neurochem.
2008;105:192e202.
39. Chen Z, Ye X, Tang N, et al. The histone acetylranseferase
hMOF acetylates Nrf2 and regulates anti-drug responses in
human non-small cell lung cancer. Br J Pharmacol.
2014;171:3196e3211.
40. Hammerman PS, Lawrence MS, Voet D, et al. Comprehensive
genomic characterization of squamous cell lung cancers. Nature.
2012;489:519e525.
41. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional
KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS
Med. 2006;3:e420.
42. Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function
activates Nrf2 and provides advantages for lung cancer cell
growth. Cancer Res. 2008;68:1303e1309.
43. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hyper-
methylation of the Keap1 gene in human lung cancer cell
lines and lung cancer tissues. Biochem Biophys Res Commun.
2008;373:151e154.
44. Kim YR, Oh JE, Kim MS, et al. Oncogenic NRF2 mutations in
squamous cell carcinomas of oesophagus and skin. J Pathol.
2010;220:446e451.45. Shibata T, OhtaT, TongKI, et al. Cancer relatedmutations inNRF2
impair its recognition by Keap1-Cul3 E3 ligase and promote ma-
lignancy. Proc Natl Acad Sci U S A. 2008;105:13568e13573.
46. Hast BE, Cloer EW, Goldfarb D, et al. Cancer-derived mutations
in KEAP1 impair NRF2 degradation but not ubiquitination.
Cancer Res. 2014;74:808e817.
47. Li QK, Singh A, Biswal S, Askin F, Gabrielson E. KEAP1 gene
mutations and NRF2 activation are common in pulmonary
papillary adenocarcinoma. J Hum Genet. 2011;56:230e234.
48. Sasaki H, Shitara M, Yokota K, et al. Increased NRF2 gene
(NFE2L2) copy number correlates with mutations in lung
squamous cell carcinomas. Mol Med Rep. 2012;6:391e394.
49. Yang Y, Jiang S, Yan J, et al. An overview of the molecular
mechanisms and novel roles of Nrf2 in neurodegenerative dis-
orders. Cytokine Growth Factor Rev. 2015;26:47e57.
50. Kikuchi N, Ishii Y, Morishima Y, et al. Nrf2 protects against
pulmonary fibrosis by regulating the lung oxidant level and Th1/
Th2 balance. Respir Res. 2010;11:31.
51. Cheung KL, Lee JH, Khor TO, et al. Nrf2 knockout enhances
intestinal tumorigenesis in Apc(min/þ) mice due to attenuation
of anti-oxidative stress pathway while potentiates inflammation.
Mol Carcinog. 2014;53:77e84.
52. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of
anticarcinogenic protective enzymes from broccoli: isolation and
elucidation of structure. Proc Natl Acad Sci U S A.
1992;89:2399e2403.
53. Chen B, Zhang Y, Wang Y, Rao J, Jiang X, Xu Z. Curcumin
inhibits proliferation of breast cancer cells through Nrf2-
mediated down-regulation of Fen1 expression. J Steroid Bio-
chem Mol Biol. 2014;143C:11e18.
54. Yuan JH, Li YQ, Yang XY. Inhibition of epigallocatechin gallate
on orthotopic colon cancer by upregulating the Nrf2-UGT1A
signal pathway in nude mice. Pharmacology. 2007;80:269e278.
55. Turpaev KT. Keap1-Nrf2 signaling pathway: mechanisms of
regulation and role in protection of cells against toxicity caused
by xenobiotics and electrophiles. Biochem (Mosc).
2013;78:111e126.
56. Iida K, Itoh K, Kumagai Y, et al. Nrf2 is essential for the che-
mopreventive efficacy of oltipraz against urinary bladder carci-
nogenesis. Cancer Res. 2004;64:6424e6431.
57. Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G,
Bishayee A. Oleanolic acid and its synthetic derivatives for the
prevention and therapy of cancer: preclinical and clinical evi-
dence. Cancer Lett. 2014;346:206e216.
58. Rachakonda G, Sekhar KR, Jowhar D, et al. Increased cell
migration and plasticity in Nrf2-deficient cancer cell lines.
Oncogene. 2010;29:3703e3714.
59. Hiramoto K, Satoh H, Suzuki T, et al. Myeloid lineage-specific
deletion of antioxidant system enhances tumor metastasis.
Cancer Prev Res (Phila). 2014;7:835e844.
60. Kanamori M, Higa T, Sonoda Y, et al. Activation of the NRF2
pathway and its impact on the prognosis of anaplastic glioma
patients. Neuro Oncol. 2015;17:555e565.
61. Kawasaki Y, Okumura H, Uchikado Y, et al. Nrf2 is useful for
predicting the effect of chemoradiation therapy on esophageal
squamous cell carcinoma. Ann Surg Oncol. 2014;21:
2347e2352.
62. Park JY, Kim YW, Park YK. Nrf2 expression is associated with
poor outcome in osteosarcoma. Pathology. 2012;44:617e621.
63. Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for
defects of Keap1 activity provoked by its point mutations in lung
cancer. Mol Cell. 2006;21:689e700.
185Y.-H. Tong et al. / Chronic Diseases and Translational Medicine 1 (2015) 175e18664. Zhang B, Xie C, Zhong J, Chen H, Zhang H, Wang X. A549 cell
proliferation inhibited by RNAi mediated silencing of the Nrf2
gene. Biomed Mater Eng. 2014;24:3905e3916.
65. Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell pro-
liferation and resistance to anticancer drugs in human lung
cancer. Clin Cancer Res. 2009;15:3423e3432.
66. Ji L, Li H, Gao P, et al. Nrf2 pathway regulates multidrug-
resistance-associated protein 1 in small cell lung cancer. PLoS
One. 2013;8:e63404.
67. Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance
of cancer cells to chemotherapeutic drugs, the dark side of Nrf2.
Carcinogenesis. 2008;29:1235e1243.
68. Tao S, Wang S, Moghaddam SJ, et al. Oncogenic KRAS confers
chemoresistance by upregulating NRF2. Cancer Res.
2014;74:7430e7441.
69. Zhou S, Ye W, Shao Q, Zhang M, Liang J. Nrf2 is a potential
therapeutic target in radioresistance in human cancer. Crit Rev
Oncol Hematol. 2013;88:706e715.
70. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. Gain of
Nrf2 function in non-small-cell lung cancer cells confers radi-
oresistance. Antioxid Redox Signal. 2010;13:1627e1637.
71. Merikallio H, Paakko P, Kinnula VL, Harju T, Soini Y. Nuclear
factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic
factors in lung cancer. Hum Pathol. 2012;43:577e584.
72. Atwell LL, Hsu A, Wong CP, et al. Absorption and chemo-
preventive targets of sulforaphane in humans following con-
sumption of broccoli sprouts or a myrosinase-treated broccoli
sprout extract. Mol Nutr Food Res. 2015;59:424e433.
73. Conaway CC, Wang CX, Pittman B, et al. Phenethyl isothio-
cyanate and sulforaphane and their N-acetylcysteine conjugates
inhibit malignant progression of lung adenomas induced by to-
bacco carcinogens in A/J mice. Cancer Res. 2005;65:
8548e8557.
74. Lenzi M, Fimognari C, Hrelia P. Sulforaphane as a promising
molecule for fighting cancer. Cancer Treat Res. 2014;159:
207e223.
75. Nioi P, McMahon M, Itoh K, Yamamoto M, Hayes JD. Identi-
fication of a novel Nrf2-regulated antioxidant response element
(ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene:
reassessment of the ARE consensus sequence. Biochem J.
2003;374:337e348.
76. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW,
Yamamoto M, Biswal S. Identification of Nrf2-regulated genes
induced by the chemopreventive agent sulforaphane by oligo-
nucleotide microarray. Cancer Res. 2002;62:5196e5203.
77. Hong F, Freeman ML, Liebler DC. Identification of sensor
cysteines in human Keap1 modified by the cancer chemo-
preventive agent sulforaphane. Chem Res Toxicol.
2005;18:1917e1926.
78. Hu C, Eggler AL, Mesecar AD, van Breemen RB. Modification
of keap1 cysteine residues by sulforaphane. Chem Res Toxicol.
2011;24:515e521.
79. Cheung KL, Kong AN. Molecular targets of dietary phenethyl
isothiocyanate and sulforaphane for cancer chemoprevention.
AAPS J. 2010;12:87e97.
80. Rahmani AH, Al Zohairy MA, Aly SM, Khan MA. Curcumin: a
potential candidate in prevention of cancer via modulation of
molecular pathways. Biomed Res Int. 2014;2014:761608.
81. Vanisree AJ, Sudha N. Curcumin combats against cigarette
smoke and ethanol-induced lipid alterations in rat lung and liver.
Mol Cell Biochem. 2006;288:115e123.82. Kalpana C, Menon VP. Curcumin ameliorates oxidative stress
during nicotine-induced lung toxicity in Wistar rats. Ital J Bio-
chem. 2004;53:82e86.
83. Malhotra A, Nair P, Dhawan DK. Premature mitochondrial
senescence and related ultrastructural changes during lung
carcinogenesis modulation by curcumin and resveratrol. Ultra-
struct Pathol. 2012;36:179e184.
84. Chen P, Li J, Jiang H, Lan T, Chen Y. Curcumin reverses
cisplatin resistance in cisplatin-resistant lung caner cells by
inhibiting FA/BRCA pathway. Tumour Biol.
2015;36:3591e3599.
85. Balogun E, Hoque M, Gong P, et al. Curcumin activates the
haem oxygenase-1 gene via regulation of Nrf2 and the
antioxidant-responsive element. Biochem J. 2003;371:887e895.
86. Howells LM, Mahale J, Sale S, et al. Translating curcumin to
the clinic for lung cancer prevention: evaluation of the pre-
clinical evidence for its utility in primary, secondary, and ter-
tiary prevention strategies. J Pharmacol Exp Ther. 2014;350:
483e494.
87. Mukhtar H, Ahmad N. Mechanism of cancer chemopreventive
activity of green Tea. Proc Soc Exp Biol Med. 1999;220:
234e238.
88. Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q. Com-
bination of low concentration of (-)-Epigallocatechin gallate
(EGCG) and curcumin strongly suppresses the growth of non-
small cell lung cancer in vitro and in vivo through causing cell
cycle arrest. Int J Mol Sci. 2013;14:12023e12036.
89. Akyol S, Ozturk G, Ginis Z, Armutcu F, Yigitoglu MR, Akyol O.
In vivo and in vitro antineoplastic actions of caffeic acid phe-
nethyl ester (CAPE): therapeutic perspectives. Nutr Cancer.
2013;65:515e526.
90. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the
in vivo evidence. Nat Rev Drug Discov. 2006;5:493e506.
91. Ren D, Villeneuve NF, Jiang T, et al. Brusatol enhances the
efficacy of chemotherapy by inhibiting the Nrf2-mediated de-
fense mechanism. Proc Natl Acad Sci U S A. 2011;108:
1433e1438.
92. Olayanju A, Copple IM, Bryan HK, et al. Brusatol provokes a
rapid and transient inhibition of Nrf2 signaling and sensitizes
mammalian cells to chemical toxicity-implications for thera-
peutic targeting of Nrf2. Free Radic Biol Med.
2015;78:202e212.
93. Tang X, Wang H, Fan L, et al. Luteolin inhibits Nrf2 leading to
negative regulation of the Nrf2/ARE pathway and sensitization
of human lung carcinoma A549 cells to therapeutic drugs. Free
Radic Biol Med. 2011;50:1599e1609.
94. Chian S, Thapa R, Chi Z, Wang XJ, Tang X. Luteolin inhibits the
Nrf2 signaling pathway and tumor growth in vivo. Biochem
Biophys Res Commun. 2014;447:602e608.
95. Chian S, Li YY, Wang XJ, Tang XW. Luteolin sensitizes two
oxaliplatin-resistant colorectal cancer cell lines to chemothera-
peutic drugs via inhibition of the Nrf2 pathway. Asian Pac J
Cancer Prev. 2014;15:2911e2916.
96. Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with
potential for cancer prevention and therapy. Curr Cancer Drug
Targets. 2008;8:634e646.
97. Arlt A, Sebens S, Krebs S, et al. Inhibition of the Nrf2 tran-
scription factor by the alkaloid trigonelline renders pancreatic
cancer cells more susceptible to apoptosis through decreased
proteasomal gene expression and proteasome activity. Oncogene.
2013;32:4825e4835.
186 Y.-H. Tong et al. / Chronic Diseases and Translational Medicine 1 (2015) 175e18698. Hirakawa N, Okauchi R, Miura Y, Yagasaki K. Anti-invasive
activity of niacin and trigonelline against cancer cells. Biosci
Biotechnol Biochem. 2005;69:653e658.
99. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M,
Weiderpass E, Bray F. International trends in lung cancer inci-
dence by histological subtype: adenocarcinoma stabilizing inmen but still increasing in women. Lung Cancer.
2014;84:13e22.
100. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or
chemotherapy for non-small-cell lung cancer with mutated
EGFR. N Engl J Med. 2010;362:2380e2388.Edited by Xiu-Yuan Hao
